Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
ayvakit save search
Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting
Published: 2024-02-23 (Crawled : 13:00) - prnewswire.com
BPMC | $86.87 -2.28% -2.34% 800K
|
Health Technology
|
| O: 0.8%
H: 5.19%
C: 3.23%
ayvakit disease cell research meeting
Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis
Published: 2023-12-12 (Crawled : 13:00) - prnewswire.com
BPMC | $86.87 -2.28% -2.34% 800K
|
Health Technology
|
| O: 0.01%
H: 5.33%
C: 4.94%
ayvakyt first approval treatment
Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis
Published: 2023-11-10 (Crawled : 13:00) - prnewswire.com
BPMC | $86.87 -2.28% -2.34% 800K
|
Health Technology
|
| O: 1.15%
H: 2.66%
C: 1.62%
ayvakyt chmp positive therapy
QIAGEN receives FDA approval for companion diagnostic to Blueprint Medicines’ AYVAKIT® (avapritinib) in gastrointestinal stromal tumors
Published: 2023-08-07 (Crawled : 20:00) - globenewswire.com
QGEN | $40.0 1.34% 0.0% 1.1M
|
Health Technology
|
| O: -0.35%
H: 0.02%
C: -1.02%
QGEN | $40.0 1.34% 0.0% 1.1M
|
Health Technology
|
| O: -1.28%
H: 0.02%
C: -1.02%
BPMC | $86.87 -2.28% -2.34% 800K
|
Health Technology
|
| O: -0.45%
H: 1.83%
C: -0.06%
ayvakit fda diagnostic approval tumors companion gastrointestinal
NEJM Evidence Publishes Results from Registrational PIONEER Trial Demonstrating Significant Clinical Benefits of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis
Published: 2023-05-23 (Crawled : 22:00) - biospace.com/
BPMC | $86.87 -2.28% -2.34% 800K
|
Health Technology
|
| O: 2.51%
H: 3.87%
C: 1.46%
ayvakit trial results benefits
Blueprint Adds Indolent Systemic Mastocytosis to Ayvakit’s Label
Published: 2023-05-23 (Crawled : 15:00) - biospace.com/
BPMC | $86.87 -2.28% -2.34% 800K
|
Health Technology
|
| O: 2.51%
H: 3.87%
C: 1.46%
label
FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis
Published: 2023-05-22 (Crawled : 20:00) - prnewswire.com
BPMC | $86.87 -2.28% -2.34% 800K
|
Health Technology
|
| O: 2.51%
H: 3.87%
C: 1.46%
ayvakit fda treatment
Blueprint Medicines Presents Registrational Data from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting
Published: 2023-02-26 (Crawled : 20:20) - prnewswire.com
BPMC | $86.87 -2.28% -2.34% 800K
|
Health Technology
|
| O: 1.08%
H: 6.12%
C: 5.58%
ayvakit meeting trial
Blueprint Medicines to Present Positive Data from PIONEER Trial of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting
Published: 2023-02-03 (Crawled : 14:20) - prnewswire.com
BPMC | $86.87 -2.28% -2.34% 800K
|
Health Technology
|
| O: -2.06%
H: 2.62%
C: -4.99%
ayvakit meeting trial positive
Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis
Published: 2023-01-23 (Crawled : 13:20) - prnewswire.com
BPMC | $86.87 -2.28% -2.34% 800K
|
Health Technology
|
| O: -0.24%
H: 1.29%
C: -0.15%
ayvakit treatment fda drug application
Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis
Published: 2022-11-22 (Crawled : 22:00) - prnewswire.com
BPMC | $86.87 -2.28% -2.34% 800K
|
Health Technology
|
| O: 0.23%
H: 5.68%
C: 2.66%
ayvakit treatment fda drug application
Analysis Group Announces Study Using Real-World Evidence to Support Blueprint Medicines' AYVAKYT® (avapritinib) Label Expansion for Advanced Systemic Mastocytosis in Europe
Published: 2022-08-17 (Crawled : 13:20) - prnewswire.com
BPMC | $86.87 -2.28% -2.34% 800K
|
Health Technology
|
| O: -21.6%
H: 19.97%
C: 13.83%
ayvakyt europe expansion label study group
Blueprint Medicines Announces Positive Top-line Results from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Non-Advanced Systemic Mastocytosis Achieving Primary and All Key Secondary Endpoints
Published: 2022-08-17 (Crawled : 12:00) - biospace.com/
BPMC | $86.87 -2.28% -2.34% 800K
|
Health Technology
|
| O: -21.6%
H: 19.97%
C: 13.83%
ayvakit trial positive results
Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval for the Treatment of Adults with Advanced Systemic Mastocytosis
Published: 2022-03-25 (Crawled : 18:00) - biospace.com/
BPMC | $86.87 -2.28% -2.34% 800K
|
Health Technology
|
| O: 0.0%
H: 0.38%
C: -2.5%
ayvakyt treatment approval
Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion for the Treatment of Adults with Advanced Systemic Mastocytosis
Published: 2022-01-28 (Crawled : 14:00) - biospace.com/
BPMC | $86.87 -2.28% -2.34% 800K
|
Health Technology
|
| O: 0.76%
H: 1.51%
C: 1.42%
ayvakyt treatment system positive chmp
Nature Medicine Publishes Results from Two Registration Studies of AYVAKIT® (avapritinib) Showing Sustained Benefits in Patients with Advanced Systemic Mastocytosis
Published: 2021-12-06 (Crawled : 23:00) - biospace.com/
BPMC | $86.87 -2.28% -2.34% 800K
|
Health Technology
|
| O: -0.28%
H: 0.0%
C: 0.0%
results
FDA Approves Blueprint Medicines' AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis
Published: 2021-06-16 (Crawled : 20:00) - prnewswire.com
BPMC | $86.87 -2.28% -2.34% 800K
|
Health Technology
|
| O: -0.81%
H: 3.66%
C: -1.58%
treatment fda fda approval approval
Blueprint Medicines Announces EMA Validation of Type II Variation Marketing Authorization Application for AYVAKYT® (avapritinib) for the Treatment of Advanced Systemic Mastocytosis
Published: 2021-03-03 (Crawled : 17:00) - biospace.com/
BPMC | $86.87 -2.28% -2.34% 800K
|
Health Technology
|
| O: -0.34%
H: 1.22%
C: -5.52%
treatment authorized ema
Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT™ (avapritinib) for the Treatment of Advanced Systemic Mastocytosis
Published: 2020-12-17 (Crawled : 15:01) - biospace.com/
BPMC | $86.87 -2.28% -2.34% 800K
|
Health Technology
|
| O: 0.01%
H: 0.78%
C: 0.66%
drug fda treatment new drug application
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.